Literature DB >> 3479419

Comparative pharmacokinetics of ciprofloxacin and ofloxacin in cystic fibrosis patients.

S S Pedersen1, T Jensen, E F Hvidberg.   

Abstract

The steady state pharmacokinetic properties of ciprofloxacin and ofloxacin were compared in cystic fibrosis patients. In a cross-over study eighteen adult patients with chronic Pseudomonas aeruginosa lung infection were given either oral ciprofloxacin 750 mg bid or oral ofloxacin 400 mg bid for two weeks. Three months later the alternative treatment was given. Concentrations were determined by a microbiological assay. Mean serum concentrations of ofloxacin (peak 5.9 mg/l) were higher than for ciprofloxacin (peak 4.0 mg/l). The time to reach maximal concentrations did not differ. The apparent total body clearance was significantly greater for ciprofloxacin, but renal clearances were similar. Relative to ofloxacin ciprofloxacin had a significantly shorter serum elimination half-life (3.4 vs. 6.4 h), showed less penetration into sputum (18% vs. 79%) and a lesser amount was recovered in urine (21% vs. 71% up to 12 h after dosing). No correlation was found between any pharmacokinetic parameter and change in pulmonary function.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3479419     DOI: 10.1093/jac/20.4.575

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  16 in total

Review 1.  Pharmacokinetic and Pharmacodynamic Optimization of Antibiotic Therapy in Cystic Fibrosis Patients: Current Evidences, Gaps in Knowledge and Future Directions.

Authors:  Charlotte Roy; Manon Launay; Sophie Magréault; Isabelle Sermet-Gaudelus; Vincent Jullien
Journal:  Clin Pharmacokinet       Date:  2021-01-24       Impact factor: 6.447

Review 2.  Ofloxacin. A reappraisal of its antimicrobial activity, pharmacology and therapeutic use.

Authors:  P A Todd; D Faulds
Journal:  Drugs       Date:  1991-11       Impact factor: 9.546

3.  Quantitative contributions of target alteration and decreased drug accumulation to Pseudomonas aeruginosa fluoroquinolone resistance.

Authors:  Sebastian Bruchmann; Andreas Dötsch; Bianka Nouri; Iris F Chaberny; Susanne Häussler
Journal:  Antimicrob Agents Chemother       Date:  2012-12-28       Impact factor: 5.191

4.  Penetration of ciprofloxacin into bronchial secretions from mechanically ventilated patients with nosocomial bronchopneumonia.

Authors:  P Saux; C Martin; M N Mallet; L Papazian; B Bruguerolle; P De Micco; F Gouin
Journal:  Antimicrob Agents Chemother       Date:  1994-04       Impact factor: 5.191

Review 5.  Fluoroquinolones in the treatment of cystic fibrosis.

Authors:  N Høiby; S S Pedersen; T Jensen; N H Valerius; C Koch
Journal:  Drugs       Date:  1993       Impact factor: 9.546

6.  Bioequivalence of oral and intravenous ofloxacin after multiple-dose administration to healthy male volunteers.

Authors:  S C Flor; M C Rogge; A T Chow
Journal:  Antimicrob Agents Chemother       Date:  1993-07       Impact factor: 5.191

Review 7.  Fluoroquinolones in the treatment of bronchopulmonary disease in cystic fibrosis.

Authors:  Matthew Hurley; Alan Smyth
Journal:  Ther Adv Respir Dis       Date:  2012-09-11       Impact factor: 4.031

Review 8.  Ciprofloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  D M Campoli-Richards; J P Monk; A Price; P Benfield; P A Todd; A Ward
Journal:  Drugs       Date:  1988-04       Impact factor: 9.546

Review 9.  Fluoroquinolones in the treatment of cystic fibrosis: a critical appraisal.

Authors:  M LeBel
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-04       Impact factor: 3.267

Review 10.  Fluoroquinolone antimicrobial agents.

Authors:  J S Wolfson; D C Hooper
Journal:  Clin Microbiol Rev       Date:  1989-10       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.